Literature DB >> 30251416

Lymphocytes are a major source of circulating soluble dipeptidyl peptidase 4.

A Casrouge1,2, A V Sauer3, R Barreira da Silva4, M Tejera-Alhambra5, S Sánchez-Ramón5, C Cancrini6,7, M A Ingersoll1,2, A Aiuti3, M L Albert1,2,4.   

Abstract

Dipeptidyl peptidase 4 (DPP4, CD26) is a serine protease that is expressed constitutively by many haematopoietic and non-haematopoietic tissues. It exists as a membrane-associated protein, as well as in an active, soluble form (herein called sDPP4), present at high concentrations in bodily fluids. Despite the proposed use of sDPP4 as a biomarker for multiple diseases, its cellular sources are not well defined. Here, we report that individuals with congenital lymphocyte immunodeficiency had markedly lower serum concentrations of sDPP4, which were restored upon successful treatment and restoration of lymphocyte haematopoiesis. Using irradiated lymphopenic mice and wild-type to Dpp4-/- reciprocal bone marrow chimeric animals, we found that haematopoietic cells were a major source of circulating sDPP4. Furthermore, activation of human and mouse T lymphocytes resulted in increased sDPP4, providing a mechanistic link between immune system activation and sDPP4 concentration. Finally, we observed that acute viral infection induced a transient increase in sDPP4, which correlated with the expansion of antigen-specific CD8+ T cell responses. Our study demonstrates that sDPP4 concentrations are determined by the frequency and activation state of lymphocyte populations. Insights from these studies will support the use of sDPP4 concentration as a biomarker for inflammatory and infectious diseases.
© 2018 British Society for Immunology.

Entities:  

Keywords:  T cells; chemokines; immunodeficiency diseases

Mesh:

Substances:

Year:  2018        PMID: 30251416      PMCID: PMC6194339          DOI: 10.1111/cei.13163

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  62 in total

1.  Determination of adenosine deaminase binding domain on CD26 and its immunoregulatory effect on T cell activation.

Authors:  R P Dong; K Tachibana; M Hegen; Y Munakata; D Cho; S F Schlossman; C Morimoto
Journal:  J Immunol       Date:  1997-12-15       Impact factor: 5.422

Review 2.  CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes.

Authors:  M D Gorrell; V Gysbers; G W McCaughan
Journal:  Scand J Immunol       Date:  2001-09       Impact factor: 3.487

3.  Binding to human dipeptidyl peptidase IV by adenosine deaminase and antibodies that inhibit ligand binding involves overlapping, discontinuous sites on a predicted beta propeller domain.

Authors:  C A Abbott; G W McCaughan; M T Levy; W B Church; M D Gorrell
Journal:  Eur J Biochem       Date:  1999-12

Review 4.  Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides.

Authors:  R Mentlein
Journal:  Regul Pept       Date:  1999-11-30

5.  Identifying neuropeptide Y (NPY) as the main stress-related substrate of dipeptidyl peptidase 4 (DPP4) in blood circulation.

Authors:  Leona Wagner; Florian Kaestner; Raik Wolf; Harald Stiller; Ulrich Heiser; Susanne Manhart; Torsten Hoffmann; Jens-Ulrich Rahfeld; Hans-Ulrich Demuth; Matthias Rothermundt; Stephan von Hörsten
Journal:  Neuropeptides       Date:  2016-02-27       Impact factor: 3.286

6.  Anti-CD26 autoantibodies are involved in rheumatoid arthritis and show potential clinical interest.

Authors:  Oscar J Cordero; Rubén Varela-Calviño; Tania López-González; Milica Grujic; Zorica Juranic; Coral Mouriño; Íñigo Hernández-Rodríguez; Marina Rodríguez-López; Bruno Aspe de la Iglesia; José María Pego-Reigosa
Journal:  Clin Biochem       Date:  2017-06-06       Impact factor: 3.281

7.  Quantitative immunogold localization of dipeptidyl peptidase IV (DPP IV) in rat liver cells.

Authors:  Y Fukui; A Yamamoto; T Kyoden; K Kato; Y Tashiro
Journal:  Cell Struct Funct       Date:  1990-04       Impact factor: 2.212

8.  CD26: a negative selection marker for human Treg cells.

Authors:  Francisco J Salgado; Amparo Pérez-Díaz; Nora M Villanueva; Olaya Lamas; Pilar Arias; Montserrat Nogueira
Journal:  Cytometry A       Date:  2012-09-04       Impact factor: 4.355

Review 9.  On the origin of serum CD26 and its altered concentration in cancer patients.

Authors:  Oscar J Cordero; Francisco J Salgado; Montserrat Nogueira
Journal:  Cancer Immunol Immunother       Date:  2009-06-26       Impact factor: 6.968

10.  KLK5 induces shedding of DPP4 from circulatory Th17 cells in type 2 diabetes.

Authors:  Titli Nargis; Krishna Kumar; Amrit Raj Ghosh; Amit Sharma; Dipayan Rudra; Debrup Sen; Saikat Chakrabarti; Satinath Mukhopadhyay; Dipyaman Ganguly; Partha Chakrabarti
Journal:  Mol Metab       Date:  2017-09-27       Impact factor: 7.422

View more
  24 in total

1.  Degranulation of human cytotoxic lymphocytes is a major source of proteolytically active soluble CD26/DPP4.

Authors:  Marcus Lettau; Michelle Dietz; Sarah Vollmers; Fred Armbrust; Christian Peters; Thi Mai Dang; Guranda Chitadze; Dieter Kabelitz; Ottmar Janssen
Journal:  Cell Mol Life Sci       Date:  2019-07-12       Impact factor: 9.261

2.  Sex-Based Differences in Human Neutrophil Chemorepulsion.

Authors:  Kristen M Consalvo; Sara A Kirolos; Chelsea E Sestak; Richard H Gomer
Journal:  J Immunol       Date:  2022-07-06       Impact factor: 5.426

3.  Polyalthia Clerodane Diterpene Potentiates Hypoglycemia via Inhibition of Dipeptidyl Peptidase 4.

Authors:  Po-Kai Huang; Shian-Ren Lin; Jirawat Riyaphan; Yaw-Syan Fu; Ching-Feng Weng
Journal:  Int J Mol Sci       Date:  2019-01-27       Impact factor: 5.923

4.  Expansion of different subpopulations of CD26-/low T cells in allergic and non-allergic asthmatics.

Authors:  Juan José Nieto-Fontarigo; Francisco Javier Salgado; María Esther San-José; María Jesús Cruz; Luis Valdés; Amparo Pérez-Díaz; Pilar Arias; Montserrat Nogueira; Francisco Javier González-Barcala
Journal:  Sci Rep       Date:  2019-05-17       Impact factor: 4.379

5.  Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans.

Authors:  Laurie L Baggio; Elodie M Varin; Jacqueline A Koehler; Xiemin Cao; Yuliya Lokhnygina; Susanna R Stevens; Rury R Holman; Daniel J Drucker
Journal:  Nat Commun       Date:  2020-07-28       Impact factor: 14.919

6.  Hematopoietic cell- versus enterocyte-derived dipeptidyl peptidase-4 differentially regulates triglyceride excursion in mice.

Authors:  Elodie M Varin; Antonio A Hanson; Jacqueline L Beaudry; My-Anh Nguyen; Xiemin Cao; Laurie L Baggio; Erin E Mulvihill; Daniel J Drucker
Journal:  JCI Insight       Date:  2020-08-20

Review 7.  DPP4 Inhibitors and COVID-19-Holy Grail or Another Dead End?

Authors:  Alicja Krejner-Bienias; Katarzyna Grzela; Tomasz Grzela
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2021-02-02       Impact factor: 4.291

Review 8.  An expanded role for dipeptidyl peptidase 4 in cell regulation.

Authors:  James Ropa; Hal E Broxmeyer
Journal:  Curr Opin Hematol       Date:  2020-07       Impact factor: 3.218

Review 9.  Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions.

Authors:  Shiying Shao; QinQin Xu; Xuefeng Yu; Ruping Pan; Yong Chen
Journal:  Pharmacol Ther       Date:  2020-02-14       Impact factor: 12.310

10.  Investigation of CD26, a potential SARS-CoV-2 receptor, as a biomarker of age and pathology.

Authors:  Animesh Alexander Raha; Subhojit Chakraborty; James Henderson; Elizabeta Mukaetova-Ladinska; Shahid Zaman; John Trowsdale; Ruma Raha-Chowdhury
Journal:  Biosci Rep       Date:  2020-12-23       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.